Annexin V antibodies in multiple sclerosis and SLE/APS

• Authors: Marta Baleva , Detelina Stoilova , Petko Shotekov , Krasimir Nikolov
• Languages of publication: EN

Abstracts

EN

Multiple sclerosis (MS) is an autoimmune disease with unclear etiopathogenesis. Some MS patients have anticardiolipin (ACL), anti-beta-2-glycoprotein-I (B2GPI) and anti-annexin V (AnV) antibodies. These antibodies can also be found in systemic lupus erythematosus with antiphospholipid syndrome (SLE/APS). The aim of our study was to compare the levels of ACL, B2GPI and AnV antibodies in MS and SLE/APS. Materials and methods: We investigated serum levels of IgG and IgM ACL, B2GPI and AnV in 21 MS patients, 30 SLE/APS patients and 30 controls using ELISA. Results: Mean levels of IgM and IgG ACL and B2GPI in MS were comparable with controls and lower than SLE/APS (p<0.05). Mean levels of IgM AnV in MS were higher compared to SLE/APS and controls (p<0.05); mean levels of IgG AnV in MS were higher than normal but similar to SLE/APS (p>0.05). Discussion: The results show that MS with negative “classic” autoantibodies (ACL and B2GPI) and without clinical data for antiphospholipid syndrome may have other positive antiphospholipid antibodies, such as AnV. Larger studies are needed to clarify whether AnV are epiphenomenon of the vascular and organ damage or they play a pathogenic role in the development of MS.

Keywords

EN

Multiple sclerosis; SLE/APS; Antibodies to annexin V

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 2
• Pages: 225-228

Dates

published

1 - 4 - 2013

online

23 - 1 - 2013

Contributors

author

Marta Baleva

• Department of Clinical Immunology, University Hospital Alexandrovska, 1.G. Sofiiski Str., Sofia, 1431, Bulgaria

author

Detelina Stoilova

• Clinic of Neurology, University Hospital “St Ivan Rilski”, Sofia, Bulgaria

author

Petko Shotekov

• Clinic of Neurology, University Hospital “St Ivan Rilski”, Sofia, Bulgaria

author

Krasimir Nikolov

• Department of Clinical Immunology, University Hospital Alexandrovska, 1.G. Sofiiski Str., Sofia, 1431, Bulgaria

References

• [1] Kaburaki J., Kuwana M., Yamamoto M., Kawai Sh., Ikeda Y., Clinical significance of anti annexin V antibodies in patients with systemic lupus erythematosus, Am. J. Hematol., 1997, 54, 209–213 http://dx.doi.org/10.1002/(SICI)1096-8652(199703)54:3<209::AID-AJH6>3.0.CO;2-#[Crossref]
• [2] Matsuda J., Saitoch N., Gohchi K., Gotoh M., Tsukamoto M., Anti annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody, Am. J. Hematol., 1994, 47, 56–58 http://dx.doi.org/10.1002/ajh.2830470112[Crossref]
• [3] Satoh A., Suzuki K., Takayama E., Kojima K., Hidaka T., Kawakani M., et al., Detection of anti - annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus, J. Rheumatol., 1999, 26, 1715–1720
• [4] Dubois T., Bisagni-Faure A., Coste J., Mavoungou E., Mankes C.J., Russo-Marie F., et al., High levels of antibodies to annexin V and VI in patients with rheumatoid arthritis. J. Rheumatol., 1995, 22, 1230–1234
• [5] Rodrigues-Garcia M.J., Fernandez J.A., Rodriguez A., Fernandez M.P., Gutierez C., Torre-Alonso J.C., Annexin V autoantibodies in patients with rheumatoid arthritis, Ann. Rheum. Dis., 1996, 55, 895–900 http://dx.doi.org/10.1136/ard.55.12.895[Crossref]
• [6] Ogawa A., Zhao D., Dlott J.S., Cameron G.S., Yamazaki M., Hata T., et al., Elevated anti annexin V levels in antiphospholipid syndrome and their involvement in antiphospholipid specificities, Am. J. Clin. Pathol., 2000, 114, 619–628 http://dx.doi.org/10.1309/298H-NLBU-E47G-8PYL[Crossref]
• [7] Triplett D.A., Antiphospholipid-protein antibodies: laboratory detection and clinical relevance, Thromb. Res., 1995, 78, 1–31 http://dx.doi.org/10.1016/0049-3848(95)00001-1[Crossref]
• [8] Mc Neil H.P., Simpson R.J., Chesterman C.N., Krilis S.A., Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H), Proc. Natl. Acad. Sci. USA, 1990, 87, 4120–4124 http://dx.doi.org/10.1073/pnas.87.11.4120[Crossref]
• [9] Galli M., Comfurius P., Maassen C., Memker H.C., De Baets M. H., Van Breda-Vriesman P.J.C., et al., Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor, Lancet, 1990, 335, 1544–1547 http://dx.doi.org/10.1016/0140-6736(90)91374-J[Crossref]
• [10] Fleck R.A., Rapaport S.I., Rao L.W.M., Anti - prothrombin antibodies and lupus anticoagulant, Blood, 1988, 72, 512–519
• [11] Bevers A.M., Galli M., Barbui T., Comfurins P., Zwaal R.F.A., Lupus anticagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid - bound human prothrombin, Thromb. Hemost., 1991, 66, 629–632
• [12] Roubey R.A.S., Pratt C.W., Buyon J.P., Winfield J.B., Lupus anticagulant activity of autoimmune antiphospholipid antibodies is dependent upon b2-glycoprotein I, J. Clin. Invest. 1992, 90, 1100–1104 http://dx.doi.org/10.1172/JCI115926[Crossref]
• [13] Nakamura N., Kuragaki C., Shidara Y., Yamaji K., Wada Y., Antibody to annexin V has anti-phospholipid and lupus anticoagulant activity, Am. J. Hematol., 1995, 49, 347–348 http://dx.doi.org/10.1002/ajh.2830490414[Crossref]
• [14] Ferreira S., D’Cruz D.P., Hughes G.R.V., Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?, Rheumatology,2005, 44, 434–442 http://dx.doi.org/10.1093/rheumatology/keh532[Crossref]
• [15] Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G., Multiple sclerosis, New Engl. J. Med., 2000, 343, 938–52 http://dx.doi.org/10.1056/NEJM200009283431307[Crossref]
• [16] Marullo S., Clauvel J.P., Intrator L., Danon F., Brouet J.C., Oksenhender E., Lupoid sclerosis with antiphospholipid and antimyelin antibodies, J. Rheumatol., 1993, 20, 747–749
• [17] Fukakawa T., Moriwaka F., Mukai M., Hamada T., Koike T., Tashiro K., Anticardiolipin antibodies in Japanese patients with multiple sclerosis, Acta Neurol. Scand. 1993, 88, 184–189 http://dx.doi.org/10.1111/j.1600-0404.1993.tb04214.x[Crossref]
• [18] Tourbach A., Clapin A., Gout O., Fontaine B., Liblau R., Batteux F., et al Systemic autoimmune features and multiple sclerosis: a 5 year follow-up study, Arch. Neurol., 1998, 55, 517–521 http://dx.doi.org/10.1001/archneur.55.4.517[Crossref]
• [19] Sugiyama Y., Yamamoto T., Characterization of serum antiphospholipid antibodies in patients with multiple sclerosis, Tokohu J. Exp. Med., 1996, 178, 203–215 http://dx.doi.org/10.1620/tjem.178.203[Crossref]
• [20] Bidot C.J., Horstman L.L., Jy W., Jimenez Y.Y., Bidot C., Ahn Y. C., et al., Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study, BMC Neurology, 2007, 7, 36, doi:10.1186/1471-2377-7-36 http://dx.doi.org/10.1186/1471-2377-7-36[WoS][Crossref]
• [21] Ijdo J.W., Conti-Kelly A.M., Greco P., Abedi M., Amos M., Provenzale J.M., et al., Anti - phospholipid antibodies in patients with multiple sclerosis and MS-like illness: MS or APS?, Lupus, 1999, 8, 109–115 http://dx.doi.org/10.1191/096120399678847461[Crossref]
• [22] Roussel V., Yi F., Jauberteau M.O., Couderq C., Lacomce C., Michelet V., et al. Prevalence and clinical significance of anti - phospholipid antibodies in multiple sclerosis: a study of 89 patients, J. Autoimmun., 2000, 14, 259–265 http://dx.doi.org/10.1006/jaut.2000.0367[Crossref]
• [23] Heinzief O., Weill B., Johanet C., Sazdovitch V., Caillat-Zucman S., Tournier-Lasserve E., et al., Antiardiolipidn antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial and biological characteristics, Neurol. Neurosurg. Psychiatry, 2002, 72, 647–649 http://dx.doi.org/10.1136/jnnp.72.5.647[Crossref]
• [24] Garg N., Zivadinov R., Ramanathan M., Vasiliu I., Locke J., Watts K., et al., Clinical and MRI correlates with autoreactive antibodies in multiple sclerosis patients, J. Neuroimmunol., 2007, 187, 159–165 http://dx.doi.org/10.1016/j.jneuroim.2007.04.008[Crossref]
• [25] Liedorp M., Sanchez E., van Hoogstraten I.M.W., von Blomberg B.M.E., Barkhof F., Polman C.H., et al., No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipid antibodies testing based on magnetic resonance imaging and long term follow-up, Neurol. Neurosurg. Psychiatry, 2007, 78, 1146–1148 http://dx.doi.org/10.1136/jnnp.2007.117713[Crossref]
• [26] Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R., Can neurologic manifestations of Hughes syndrome (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature, Medicine (Baltimore), 2000, 79, 57–68 http://dx.doi.org/10.1097/00005792-200001000-00006[Crossref]
• [27] Karussis D., Leker R.R., Ashkenazi A., Abramsky O., A subgroup of multiple sclerosis patients with anticardiolipidn antibodies and unusual clinical manifestations: Do they represent a new nosological entity?, Ann. Neurol., 1998, 44, 629–634 http://dx.doi.org/10.1002/ana.410440408[Crossref]
• [28] Dikova Ch., Petrova I., Nikolov K., Baleva M., Shabani R., Antiphospholipid syndrome, livedo reticularis and multiple sclerosis, Med. Pregled., 2007, 43, 57–61, (in Bulgarian)
• [29] Nojima J., Kuratsune H., Suehisa E., Futsukaichi Y., Yamanishi H., Machii T., et al., Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications, Clin. Chem., 2001, 47, 1008–1015
• [30] Horstman L.L., Jy W., Bidot C.J., Ahn Y.S. Kelley R.E., Zivadinov R., et al. Antiphospholipid antibodies: Paradigm in transition, J. Neuroinflammation, 2009, 6, 3, doi: 10.1186/1742- 2094-6-3 http://dx.doi.org/10.1186/1742-2094-6-3[Crossref]
• [31] Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., et al., Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer, Lupus, 2003, 12, 435–442
• [32] Ziporen L., Schoenfeld Y., Levy Y., Korczyn A.D., Neurological dysfunction and hyperreactive behavior associated with antiphospholipid antibodies. A mouse model. J. Clin. Invest., 1997, 100, 613–619 http://dx.doi.org/10.1172/JCI119572[Crossref]

Identifiers

DOI

10.2478/s11536-012-0107-8